Trial · NCT06819605
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
NCT06819605, Phase 2, Phase 3, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma. Trials, record NCT06819605. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06819605
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
- NCT number
- NCT06819605
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Conditions
- Ameloblastoma
- Interventions
- Dabrafenib and trametinib (combination)
- First posted
- 2025-02-11
- Last updated
- 2025-02-11
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence - free survival rates | Up to 5 years | To evaluate the recurrence-free survival after neoadjuvant therapy with dabrafenib and trametinib, followed by curettage and fenestration surgery. |
| Secondary | Radiological response | 3 months | The radiological response to neoadjuvant therapy with Dabrafenib and Trametinib in patients with ameloblastoma will be assessed through three-dimensional volumetric imaging (e.g., CT scans with 3D reconstruction) at predefined intervals. Tumor volume changes, as determined by 3D reconstruction, will be used to evaluate the radiological response. |
| Secondary | Pathological response | 4 months | The pathological response to neoadjuvant therapy with Dabrafenib and Trametinib in patients with ameloblastoma will be assessed through post-treatment surgical specimens. |
| Secondary | AEs will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | 1 year | The safety of neoadjuvant therapy with Dabrafenib and Trametinib in patients with ameloblastoma will be assessed through monitoring adverse events (AEs). AEs will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and graded based on severity (Grade 1 to Grade 5) and their relationship to the study drugs. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06819605
GET https://conductscience.org/api/trials/v1/NCT06819605/registered